Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
By K. Franco, Barbara J. Messinger-Rapport. Journal of the American Medical Directors Association, 2006
934 citations recorded by the source corpus.
Subfields: Molecular Biology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/bab408dbee960caafee671ee04842c1ac2c17080
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- Lon S. Schneider
- Andrzej S. Cichocki
- Justin H. G. Dauwels
- François-Benoît Vialatte
- Karen Stevens Dagerman
- P. Insel
In Psychiatry and Mental health
- Lon S. Schneider
- Karen Stevens Dagerman
- Michael D. Geschwind
- Michael G. Erkkinen
- Mee‐Ohk Kim
- P. Insel
Citations in the corpus
- Antipsychotic Drug Use and Mortality in Older Adults with Dementia (2007, background): “Nonpharmacologic strategies are recommended as first-line management for these symptoms (2), but they may be difficult to implement in clinical practice (3).”
- Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “Neuroleptic medications should be avoided when possible given their limited efficacy (Sink et al. 2005) and increased risk of mortality; however, sometimes these medications are necessary for severe behavioral phenotypes when nonpharmacological or other treatments are unsuccessful.”
- Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. (2005, background): “There is little clinical trials evidence supporting the efficacy of other classes of psychotropic medication, such as benzodiazepines, anticonvulsants, and antidepressants, for the treatment of aggression, psychotic symptoms, or agitation in patients with dementia.(9)”
- Diagnosis of Alzheimer's disease from EEG signals: where are we standing? (2010, background): “Diagnosis of MCI and AD is important for several reasons [4, 5, 6, 7, 8]:”
- Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. (2006, background): “chosis is limited by modest efficacy and important adverse effects.(3,15) Nonpharmacological management of behavioral symptoms is recommended as an initial approach but caregivers and clinicians often do not have the resources to provide this care.”